Taken together, these findings suggest that CD19@NP/17-DMAG plus imatinib treatment increases MHC-I expression and antigen presentation in BCR-ABL1+ B-ALL cells, which is essential for robust CD8+ T cell-mediated responses. This evidence concerns the gene CD8A and acute lymphoblastic leukemia.